Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 39,741 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 39,741 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total value of $695,070.09. Following the completion of the sale, the insider directly owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.07, for a total value of $340,039.48.
• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.08, for a total value of $430,749.44.

Adaptive Biotechnologies Trading Down 1.2%

ADPT opened at $16.70 on Tuesday. Adaptive Biotechnologies Corporation has a 1-year low of $9.90 and a 1-year high of $20.76. The stock’s fifty day simple moving average is $14.22 and its 200 day simple moving average is $15.65. The stock has a market cap of $2.67 billion, a PE ratio of -50.61 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.20) EPS. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Morgan Stanley decreased their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Guggenheim reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. TD Cowen raised their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $28,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares in the last quarter. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies during the first quarter valued at approximately $45,000. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $51,000. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.